Literature DB >> 19824790

Proteomic studies of Bacillus anthracis.

Theodor Chitlaru1, Avigdor Shafferman.   

Abstract

Bacillus anthracis is a Gram-positive, spore-forming bacterium representing the etiological cause of anthrax, a rare lethal disease of animals and humans. Development of anthrax countermeasures has gained increasing attention owing to the potential use of B. anthracis spores as a bioterror weapon. The various forms of infection by B. anthracis are characterized both by toxemia and septicemia, both of which are the result of spore entry into the host followed by their germination into rapidly multiplying, toxin-producing bacilli. Following the publication of the bacterial genome, proteomic studies were carried out to determine the protein composition of the spore and identify exposed vegetative (membrane-located or secreted) proteins. These studies included comparison of strains differing in their virulence, cultured under different conditions and, in some cases, were complemented by serological inspection, which addressed expression during infection of proteomically identified proteins and their immunogenicity. The proteomic approach emerged as a valuable strategy for the generation of a pool of potential B. anthracis protein targets for further evaluation in detection, diagnostics, therapy and prophylaxis, and contributed to the elucidation of some aspects of the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19824790     DOI: 10.2217/fmb.09.73

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  8 in total

Review 1.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

2.  Proteomic analysis of Bacillus thuringiensis at different growth phases by using an automated online two-dimensional liquid chromatography-tandem mass spectrometry strategy.

Authors:  Shaoya Huang; Xuezhi Ding; Yunjun Sun; Qi Yang; Xiuqing Xiao; Zhenping Cao; Liqiu Xia
Journal:  Appl Environ Microbiol       Date:  2012-05-25       Impact factor: 4.792

3.  Differential contribution of Bacillus anthracis toxins to pathogenicity in two animal models.

Authors:  Haim Levy; Shay Weiss; Zeev Altboum; Josef Schlomovitz; Itai Glinert; Assa Sittner; Avigdor Shafferman; David Kobiler
Journal:  Infect Immun       Date:  2012-05-14       Impact factor: 3.441

4.  Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response.

Authors:  Anat Zvi; Shahar Rotem; Erez Bar-Haim; Ofer Cohen; Avigdor Shafferman
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

5.  Experimental Validation of Bacillus anthracis A16R Proteogenomics.

Authors:  Zhiqi Gao; Zhiqiang Wang; Kun Zhang; Yanchang Li; Tao Zhang; Dongshu Wang; Xiankai Liu; Erling Feng; Lei Chang; Junjie Xu; Simin He; Ping Xu; Li Zhu; Hengliang Wang
Journal:  Sci Rep       Date:  2015-10-01       Impact factor: 4.379

6.  Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.

Authors:  Theodor Chitlaru; Ma'ayan Israeli; Erez Bar-Haim; Uri Elia; Shahar Rotem; Sharon Ehrlich; Ofer Cohen; Avigdor Shafferman
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379

7.  Whole-Genome Sequencing of the Nonproteolytic Bacillus anthracis V770-NP1-R Strain Reveals Multiple Mutations in Peptidase Loci.

Authors:  Inbar Cohen-Gihon; Ofir Israeli; Adi Beth-Din; Haim Levy; Ofer Cohen; Avigdor Shafferman; Anat Zvi; Theodor Chitlaru
Journal:  Genome Announc       Date:  2014-02-13

8.  Cloning of the Recombinant Cytochrome P450 Cyp141 Protein of Mycobacterium tuberculosis as a Diagnostic Target and Vaccine Candidate.

Authors:  Mohammad Rabiee-Faradonbeh; Davood Darban-Sarokhalil; Mohammad Mehdi Feizabadi; Amirhooshang Alvandi; Hasan Momtaz; Neda Soleimani; Abolfazl Gholipour
Journal:  Iran Red Crescent Med J       Date:  2014-11-05       Impact factor: 0.611

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.